Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

• Autores principales: Kit Wun Kathy Cheung (Autor), Yang Tang (Autor), Doreen Anders (Autor), Teresa Barata (Autor), Astrid Scalori (Autor), Priya Agarwal (Autor), Rucha Sane (Autor), Sravanthi Cheeti (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2024-04-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (<i>RET</i>) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely alter its pharmacokinetics (PK)...